188 related articles for article (PubMed ID: 25448567)
1. Extrinsic lactose fines improve dry powder inhaler formulation performance of a cohesive batch of budesonide via agglomerate formation and consequential co-deposition.
Kinnunen H; Hebbink G; Peters H; Huck D; Makein L; Price R
Int J Pharm; 2015 Jan; 478(1):53-59. PubMed ID: 25448567
[TBL] [Abstract][Full Text] [Related]
2. Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks.
Kinnunen H; Hebbink G; Peters H; Shur J; Price R
AAPS PharmSciTech; 2014 Aug; 15(4):1009-20. PubMed ID: 24831088
[TBL] [Abstract][Full Text] [Related]
3. An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations.
Kinnunen H; Hebbink G; Peters H; Shur J; Price R
AAPS PharmSciTech; 2014 Aug; 15(4):898-909. PubMed ID: 24756910
[TBL] [Abstract][Full Text] [Related]
4. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation.
Sun Y; Qin L; Li J; Su J; Song R; Zhang X; Guan J; Mao S
AAPS J; 2021 Apr; 23(3):55. PubMed ID: 33856568
[TBL] [Abstract][Full Text] [Related]
5. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
[TBL] [Abstract][Full Text] [Related]
6. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
[TBL] [Abstract][Full Text] [Related]
7. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance.
Cordts E; Steckel H
Eur J Pharm Biopharm; 2012 Oct; 82(2):417-23. PubMed ID: 22902789
[TBL] [Abstract][Full Text] [Related]
8. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
9. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
[TBL] [Abstract][Full Text] [Related]
10. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
Rawal T; Kremer L; Halloum I; Butani S
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
[TBL] [Abstract][Full Text] [Related]
11. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
12. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
Le VN; Bierend H; Robins E; Steckel H; Flament MP
Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
[TBL] [Abstract][Full Text] [Related]
13. Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations.
Hertel M; Schwarz E; Kobler M; Hauptstein S; Steckel H; Scherließ R
Int J Pharm; 2018 Jan; 535(1-2):59-67. PubMed ID: 29100914
[TBL] [Abstract][Full Text] [Related]
14. Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend.
Wauthoz N; Hennia I; Ecenarro S; Amighi K
Int J Pharm; 2018 Dec; 553(1-2):47-56. PubMed ID: 30321640
[TBL] [Abstract][Full Text] [Related]
15. The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.
Shur J; Harris H; Jones MD; Kaerger JS; Price R
Pharm Res; 2008 Jul; 25(7):1631-40. PubMed ID: 18239861
[TBL] [Abstract][Full Text] [Related]
16. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
Saboti D; Maver U; Chan HK; Planinšek O
J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981
[TBL] [Abstract][Full Text] [Related]
17. Modeling dispersion of dry powders for inhalation. The concepts of total fines, cohesive energy and interaction parameters.
Thalberg K; Berg E; Fransson M
Int J Pharm; 2012 May; 427(2):224-33. PubMed ID: 22349053
[TBL] [Abstract][Full Text] [Related]
18. Experimental investigation of design parameters on dry powder inhaler performance.
Ngoc NT; Chang L; Jia X; Lau R
Int J Pharm; 2013 Nov; 457(1):92-100. PubMed ID: 24055597
[TBL] [Abstract][Full Text] [Related]
19. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
[TBL] [Abstract][Full Text] [Related]
20. Elucidation of lactose fine size and drug shape on rheological properties and aerodynamic behavior of dry powders for inhalation.
Sun Y; Yu D; Li J; Zhao J; Feng Y; Zhang X; Mao S
Eur J Pharm Biopharm; 2022 Oct; 179():47-57. PubMed ID: 36029939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
